PT  - JOURNAL ARTICLE
AU  - Y Duncan-Roberts
AU  - Y Garcia-Vega
AU  - S Collazo-Caballero
AU  - M Rodriguez-Garcia
AU  - M Zalazar-Sedano
AU  - JL Rodríguez-Rojas
AU  - A Tuero-Iglesias
AU  - C Valenzuela-Silva
AU  - I Raices-Cruz
AU  - N Castro-Basart
AU  - E Garcia-Iglesias
AU  - L Pereda-Lamela
AU  - R Hernández-Rodríguez
AU  - E Arteaga-Hernandez
AU  - V Muzio-Gonzalez
AU  - I Bello-Rivero
TI  - Five years follow-up of patients with non-melanoma skin cancer treated with HeberFERON
AID  - 10.1101/2022.02.07.22270604
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.02.07.22270604
4099  - http://medrxiv.org/content/early/2022/02/08/2022.02.07.22270604.short
4100  - http://medrxiv.org/content/early/2022/02/08/2022.02.07.22270604.full
AB  - Introduction Non-melanoma skin cancer is the most common tumor. The combination of IFN-alpha 2b and IFN-gamma has been used as a new therapeutic opportunity to treat basal cell carcinomas and cutaneous squamous cell carcinomas. The aim of this report is to record prospectively the recurrence and new lesions rates in patients participating in phase II clinical trials.Methods Phase II clinical trials (double-blind randomized one center study, InCarbacel-III, in patients with basal cell carcinoma; and open, non-randomized multicenter study, CECIN, in patients with cutaneous squamous cell carcinomas), with the use of the combination of IFN-alpha 2b and IFN-gamma were conducted to evaluate the efficacy, safety and the 5-year duration of clinical responses. Both studies were approved by institutional ethic committees and all the patients given their written informed consent. The investigational treatment was administered, peri- or intralesionally, three times per week, during 3 weeks. Clinical (RECIST 1.0) responses were evaluated three months after the end of treatment.Results The combination of IFNs in InCarbacel-III study showed the best clinical response (complete response of 64.3%, overall response of 85.7%) with the highest doses (10.5 MIU); without patient’s recurrence at 5 years follow-up (3.5 MUI and 10.5 MUI groups). The frequency of new lesions decreased in the treated patients 8 times. In the CECIN study 14 patients achieved complete response and 4 partial responses (overall response rate 67%). Up to the 5-year follow-up none of the patients with complete response had recurrence or new lesion. In both studies the cosmetic results were excellent and the reported adverse events were mostly of mild intensity.Conclusions The use of the combination of IFN-alpha 2b and IFN-gamma showed efficacy in basal cell carcinoma and cutaneous squamous cell carcinoma promoting a long term response for at least 5 years and decreasing the rate of new lesions, safely and with excellent cosmetic effects.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCECIN study (code: IG/AGI/NE/0901, registroclinico.sld.cu/en/trials/RPCEC00000144) InCarbacel III study (code: IG/ IAIIGI/NB/0601; registroclinico.sld.cu/en/trials/RPCEC00000066Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The following ethical and/or research institutional committee waived the approval of the study in their respectively institutions in Cuba. Amalia Simoni Hospital Ethical Committee approved the study. Camaguey Province, Cuba Hermanos Ameijeiras Hospital Ethical Committee approved the study the study. Havana Province, Cuba I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesQualified individuals may request access to the de-identified participant data, anonymized clinical study reports, informed consent forms, through submission of a proposal with a defined research question to the corresponding author, Bello-Rivero Iraldo, provided that the necessary data protection and ethical committee approvals are in compliance with the trial. An agreement for transfer of these data will be required.